Cisplatin is one of the most widely used chemotherapeutic agents in the world, and it is particularly important in the treatment of cervical cancer, a disease that disproportionately strikes women in their reproductive years. While oncologists have long documented cisplatin’s toxic effects on the kidneys, ears, and nerves, its consequences for the uterus have received far less attention. This gap matters clinically. For young women with cervical cancer, fertility preservation is a growing priority, and previous reports have described unexplained uterine atrophy in patients who received neoadjuvant chemotherapy before fertility-sparing surgery. A uterus that is structurally or functionally compromised may struggle to support implantation and pregnancy even if the ovaries continue to produce eggs and hormones.

To investigate whether galaxamide could mitigate this damage, the research team, led by corresponding authors Hanlin Shuai, Bihui Guo, and Ping Li, used female mice bearing HeLa cervical cancer tumors. The animals were assigned to receive cisplatin alone or cisplatin in combination with galaxamide, and the researchers then carried out a comprehensive assessment of uterine health. Their measurements spanned multiple levels of biological organization, from gross tissue architecture down to individual signaling proteins. They examined uterine morphology under the microscope, quantified systemic inflammation by measuring circulating cytokines, tracked apoptosis or programmed cell death in the endometrial epithelium, measured the expression of molecules that define endometrial receptivity, characterized the polarization state of macrophages infiltrating the tissue, and probed the activation status of the nuclear factor kappa B, or NF-κB, inflammatory signaling pathway.

The results painted a stark picture of what cisplatin does to the mouse uterus. Animals receiving the chemotherapy drug alone showed thinning of the endometrial epithelium, the single-cell layer lining the uterine cavity, along with disorganization of the endometrial glands, the structures responsible for secreting factors essential for early pregnancy. The endometrial epithelial cells underwent elevated levels of apoptosis, driven by shifts in the expression of genes that regulate the cell death machinery. Beyond cell death, cisplatin disrupted the physical infrastructure of the lining: the integrity of desmosomes and tight junctions, the specialized protein assemblies that glue epithelial cells to one another and maintain the barrier function of the uterus, was compromised. The expression of receptivity markers, the molecular beacons that signal when the endometrium is ready to accept an implanting embryo, dropped significantly. Systemically, the cisplatin-treated mice exhibited elevated serum levels of the inflammatory cytokines interleukin-6, interleukin-18, and tumor necrosis factor-alpha, and their uteri showed increased infiltration of M1 macrophages, the pro-inflammatory subclass of immune cells, accompanied by activation of NF-κB signaling within the tissue.

Galaxamide co-treatment reversed nearly every one of these pathological changes. Mice that received the combination therapy maintained much of their normal uterine architecture, with preserved epithelial thickness and organized glandular structures. Cytokine levels in the blood fell toward baseline, apoptotic gene expression normalized, receptivity markers returned, and the desmosome and tight junction networks retained their integrity. Perhaps most strikingly, galaxamide shifted the immune landscape of the uterus, promoting the polarization of macrophages toward the M2 phenotype, an anti-inflammatory, tissue-repairing state, while simultaneously suppressing the NF-κB pathway that had been driving the inflammatory cascade. The mechanistic story that emerges is one of dual protection: galaxamide both calms inflammation and blocks apoptosis, and it appears to accomplish this largely through inhibition of NF-κB, a master transcription factor that, when activated, enters the nucleus and switches on genes encoding cytokines, survival signals, and additional inflammatory mediators.

The molecular logic of this protection is grounded in established biology. NF-κB has long been implicated in endometrial diseases in both humans and animals, and disturbed endometrial NF-κB expression has been documented in women suffering from recurrent implantation failure. Because NF-κB sits upstream of both inflammatory cytokine production and apoptosis-regulating gene networks, inhibiting it can produce broad downstream benefits, which is consistent with the wide-ranging histological and molecular rescue the researchers observed. Macrophages are also central players in this drama. These immune cells are normal, even essential, residents of the endometrium, where they participate in tissue remodeling during the menstrual cycle and support embryo implantation. But when skewed toward the M1, pro-inflammatory state, they can become a double-edged sword, and prior studies have shown that macrophage-driven inflammation exacerbates cisplatin toxicity in organs as varied as the kidney and the inner ear. By steering macrophages toward the M2 phenotype, galaxamide appears to convert a damaging immune response into a reparative one.

The study builds directly on the group’s earlier work. In 2024, members of the same team reported in BMC Cancer that galaxamide alleviated cisplatin-induced premature ovarian insufficiency in HeLa tumor-bearing mice through the PI3K signaling pathway. Galaxamide has also been shown in separate research to possess intrinsic antitumor activity against cervical cancer cells, driving apoptosis and reducing cancer stem-like properties by inhibiting the Wnt/beta-catenin pathway. Taken together, these findings position galaxamide as an unusually versatile candidate: a compound that may enhance cisplatin’s tumor-killing efficacy, protect the ovaries from chemotherapy-induced dysfunction, and now, according to the new study, protect the uterus as well. The researchers also deposited raw RNA sequencing data from the uterine transcriptomic analysis in the NCBI Gene Expression Omnibus under accession number GSE302127, providing a public resource for other investigators to mine differentially expressed genes and pathway signatures.

For patients and clinicians, the implications are tantalizing but must be interpreted with appropriate caution. The work was performed entirely in mice, and rodent reproductive biology, while sharing many molecular pathways with humans, does not perfectly recapitulate human uterine physiology. Dosing, pharmacokinetics, and long-term safety of galaxamide in humans remain unestablished, and it is not yet known whether the protective effects would extend to chemotherapy regimens beyond cisplatin or to cancer types other than cervical cancer. There is also a theoretical concern that any compound protecting normal tissue from chemotherapy could, in principle, shield tumor cells as well; however, the prior evidence that galaxamide actually increases cisplatin’s antitumor efficacy in this same model argues against that possibility and instead suggests a therapeutic window in which normal tissue is spared while malignant cells remain vulnerable.

The significance of the study also lies in what it reveals about the uterus as a target of chemotherapy toxicity. Research into gonadotoxicity has traditionally centered on the ovaries, where chemotherapy depletes the finite pool of follicles and can trigger premature ovarian insufficiency. Strategies to protect the ovaries, including gonadotropin-releasing hormone agonists and a growing list of cytoprotective natural products such as resveratrol, pycnogenol, and melatonin, have attracted substantial attention. The uterus, by contrast, has been comparatively neglected, even though successful pregnancy depends on far more than oocyte quality: it requires an endometrium with intact epithelial junctions, functional glands, properly timed receptivity marker expression, and a balanced immune environment. The new findings, together with earlier reports that cisplatin decreases the expression of the receptivity factors HOXA13 and integrin alpha-v beta-3 in the uterus, establish that platinum chemotherapy can undermine precisely these receptive features.

The experimental design of the study deserves note for its breadth. By combining histological assessment, ELISA-based cytokine measurement, Western blotting and immunostaining for signaling proteins, gene expression profiling of apoptotic markers, and macrophage phenotyping, the team assembled converging lines of evidence from independent methodologies. The inclusion of a tumor-bearing context is particularly important, because it evaluates the protective compound in the setting where it would actually be used, alongside an active tumor, rather than in healthy animals. The authors report that the work was supported by the National Natural Science Foundation of China and multiple Guangdong provincial research foundations, and the experimental protocols were approved by the Laboratory Animal Committee of Jinan University.

What comes next will likely involve validating these findings in larger animal studies, clarifying exactly how galaxamide inhibits NF-κB signaling at the biochemical level, and determining whether the M2 macrophage shift is a cause or a consequence of the reduced inflammation. If subsequent work confirms the protective effect and establishes safety, galaxamide could join a new generation of oncofertility interventions aimed not merely at preserving the ability to produce eggs, but at safeguarding the entire reproductive tract. For the growing number of young cancer survivors who hope to carry a pregnancy after treatment, that distinction could prove decisive. The study is published in Reproductive Sciences.

Doxorubicin, a cornerstone of cancer chemotherapy, is known for its efficacy in targeting a wide range of tumors. However, its use is significantly hampered by its hepatotoxicity, which manifests as liver injury, ranging from mild enzyme elevation to severe hepatic damage. This study aims to explore how myricetin could serve as a protective agent, potentially reducing the risk of doxorubicin-induced liver toxicity through the modulation of oxidative stress and inflammatory pathways.

The liver plays a crucial role in drug metabolism and detoxification, rendering it particularly vulnerable to the side effects of chemotherapeutic agents like doxorubicin. The researchers started their investigation by establishing an experimental framework to assess the hepatoprotective properties of myricetin. By treating animal models with doxorubicin and administering myricetin simultaneously, they set the stage for a rigorous evaluation of liver functions and structural integrity following exposure to the chemotherapeutic agent.

Myricetin, a flavonoid commonly found in various fruits, vegetables, and herbs, has garnered attention for its potential health benefits, particularly its antioxidant and anti-inflammatory properties. The researchers hypothesized that these characteristics could mitigate oxidative damage and inflammation triggered by doxorubicin, thereby preserving liver function and architecture. Their results indicated that myricetin administration significantly lowered markers of oxidative stress, suggesting a direct protective role against the cellular damage typically induced by chemotherapy.

Moreover, the study delved into the inflammatory aspect of liver damage, a critical consideration given that inflammation often exacerbates tissue injury. The researchers measured the levels of pro-inflammatory cytokines and other inflammatory markers in the liver tissues of the test subjects. Remarkably, they found that myricetin not only reduced oxidative stress markers but also effectively suppressed the inflammatory response associated with doxorubicin treatment. This dual action underscores myricetin’s potential as a powerful adjunct therapy in chemotherapy protocols.

The mechanisms through which myricetin exerts its protective effects were explored in depth, contributing valuable insights to the understanding of liver pharmacology. The study identified key signaling pathways through which myricetin mediates its antioxidant effects. For instance, the activation of Nrf2, a transcription factor known to regulate the expression of antioxidant proteins, was notably enhanced in the presence of myricetin. This finding illuminates an intriguing avenue for further research, as targeting the Nrf2 pathway may provide a strategic approach to bolster hepatic defense mechanisms against chemotherapeutic agents.

Additionally, the study’s findings prompted further investigations into the possible synergistic effects of myricetin with other chemotherapeutic agents. This line of inquiry holds promise for the development of combination therapies that maximize anti-cancer efficacy while minimizing hepatotoxic risks. As the quest for precision medicine continues, such insights can guide clinicians in tailoring treatment plans that better accommodate individual patient responses and minimize adverse effects.

In evaluating the clinical implications of these findings, it is crucial for oncologists and researchers to consider how myricetin could be integrated into existing treatment paradigms. The potential for myricetin to act as a hepatoprotective agent offers a glimmer of hope for patients facing the deleterious effects of chemotherapy on liver health. As the study suggests, enhancing the liver’s resilience may not only improve the quality of life for patients undergoing cancer treatment but could also potentially increase the maximum tolerable doses of chemotherapeutics, thus enhancing therapeutic outcomes.

Public response to research such as this often hinges on the relatability of the findings to everyday experiences. As awareness grows regarding the side effects of cancer treatments, the desire among patients and healthcare providers for protective measures intensifies. Studies like those by Sabir and Dyary resonate with a broad audience, opening informed discussions about the integration of natural compounds into the realm of modern medicine.

Furthermore, the widespread availability of myricetin-rich foods presents an exciting opportunity for preventive health measures. Educating patients about dietary sources of myricetin—such as berries, nuts, onions, and tea—could foster a proactive approach to liver health during chemotherapy. The convergence of dietary habits and pharmacotherapy could empower patients to take an active role in their treatment journeys, potentially mitigating some adverse effects associated with conventional therapies.

As this research paves the way for future studies, the authors emphasize the need for clinical trials to further explore the efficacy and safety of myricetin in human populations. Confirmation of these benefits in clinical settings will be critical to establish guidelines for its use alongside standard treatments. Such endeavors could lead to significant advancements in the optimization of cancer care, ensuring that patients receive comprehensive support throughout their treatment experiences.

In summary, the study conducted by Sabir and Dyary offers compelling evidence for the potential of myricetin to mitigate liver damage induced by doxorubicin. By elucidating the mechanisms of oxidative stress and inflammation modulation, this research opens new pathways for exploration in both laboratory and clinical settings. The integration of natural agents such as myricetin into cancer treatment regimens could mark a transformative step toward improved patient outcomes, underlining the importance of a multidisciplinary approach in the fight against cancer.

This groundbreaking research not only contributes to the scientific community’s understanding of chemotherapeutic safety but also emphasizes the vital role of nutrition and natural compounds in enhancing health during disease management. As the conversation around personalized medicine continues to evolve, the implications of these findings may eventually extend beyond the laboratory and into the lives of countless individuals navigating the complexities of cancer treatment.

Subject of Research: Doxorubicin-induced liver damage and the protective effects of myricetin.

Article Title: Myricetin protects against doxorubicin-induced liver damage by modulating oxidative and inflammatory pathways.

Article References:

Sabir, L.M., Dyary, H.O. Myricetin protects against doxorubicin-induced liver damage by modulating oxidative and inflammatory pathways. BMC Pharmacol Toxicol (2026). https://doi.org/10.1186/s40360-026-01088-1

Image Credits: AI Generated

DOI: 10.1186/s40360-026-01088-1

Keywords: Myricetin, Doxorubicin, Liver Damage, Oxidative Stress, Inflammation, Hepatoprotective, Cancer Therapy, Chemotherapy.